179 related articles for article (PubMed ID: 36765524)
1. An Update on the Treatment of Papillary Renal Cell Carcinoma.
Chawla NS; Sayegh N; Prajapati S; Chan E; Pal SK; Chehrazi-Raffle A
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765524
[TBL] [Abstract][Full Text] [Related]
2. A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.
Rhoades Smith KE; Bilen MA
Kidney Cancer; 2019 Nov; 3(3):151-161. PubMed ID: 31867475
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
4. Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.
Sweeney PL; Jang A; Halat SK; Pal SK; Barata PC
Cancer Treat Res Commun; 2022; 33():100639. PubMed ID: 36162322
[TBL] [Abstract][Full Text] [Related]
5. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.
Tachibana H; Inakawa T; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Anticancer Res; 2022 Jun; 42(6):3151-3158. PubMed ID: 35641290
[TBL] [Abstract][Full Text] [Related]
7. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
9. MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma.
Takahashi H; Vikram R; Jimenez RE; Bolan CW; Kawashima A; Karam JA; Takahashi N
Abdom Radiol (NY); 2021 Nov; 46(11):5250-5259. PubMed ID: 34338814
[TBL] [Abstract][Full Text] [Related]
10. Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.
Chen F; Huhdanpaa H; Desai B; Hwang D; Cen S; Sherrod A; Bernhard JC; Desai M; Gill I; Duddalwar V
Springerplus; 2015; 4():66. PubMed ID: 25694862
[TBL] [Abstract][Full Text] [Related]
11. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
12. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
[TBL] [Abstract][Full Text] [Related]
13. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics.
Krencz I; Vetlényi E; Dankó T; Petővári G; Moldvai D; Sztankovics D; Raffay R; Mészáros K; Sebestyén E; Végső G; Pápay J; Sebestyén A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142502
[TBL] [Abstract][Full Text] [Related]
15. Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast - enhanced ultrasonography.
Xue LY; Lu Q; Huang BJ; Li Z; Li CX; Wen JX; Wang WP
Eur J Radiol; 2015 Oct; 84(10):1849-56. PubMed ID: 26149528
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma.
Huang J; Huang D; Yan J; Chen T; Gao Y; Xu D; Na R
Cancer Med; 2020 Dec; 9(24):9409-9418. PubMed ID: 33141518
[TBL] [Abstract][Full Text] [Related]
17. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
Halefoglu AM; Ozagari AA
Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
de Vries-Brilland M; McDermott DF; Suárez C; Powles T; Gross-Goupil M; Ravaud A; Flippot R; Escudier B; Albigès L
Cancer Treat Rev; 2021 Sep; 99():102228. PubMed ID: 34111642
[TBL] [Abstract][Full Text] [Related]
19. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
20. Comparison of cortico-medullary phase contrast-enhanced MDCT and T2-weighted MR imaging in the histological subtype differentiation of renal cell carcinoma: radiology-pathology correlation.
Halefoglu AM; Ozagari AA
Pol J Radiol; 2021; 86():e583-e593. PubMed ID: 34876939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
